Jefferies Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Jefferies Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,585	Closed	-$22.6K	–	1850
2021 Q4	$22.6K	Buy	+1,585	New	+$33.1K	﹤0.01%	1551

Other funds holding ORMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Jefferies Group's ORMP Position: Q1 2022 in Review

Jefferies Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 1,585 shares — an estimated $22.6K sold.

Jefferies Group first reported a position in ORMP in Q4 2021 and held it in 1 quarter. The position peaked at $22.6K in Q4 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

Jefferies Group reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 1,585 Oramed Pharmaceuticals shares in Q1 2022, an estimated $22.6K.
Jefferies Group first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Jefferies Group's Oramed Pharmaceuticals position peaked at $22.6K in Q4 2021.
103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.